Gsk (GSK) Raw Materials (2013 - 2014)
Gsk (GSK) posted Raw Materials of $1.8 billion for Q4 2014, up 20.73% quarter-over-quarter from $1.5 billion in Q4 2013, and up 20.73% YoY from $1.5 billion in Q4 2013.
Powered by 
Analysis
Gsk (GSK) Raw Materials (2013 - 2014) Analysis & Trends
Gsk (GSK) has 2 years of Raw Materials data on file, last reported at $1.8 billion in Q4 2014.
- For the quarter ending Q4 2014, Raw Materials rose 20.73% year-over-year to $1.8 billion; the trailing twelve-month figure through Dec 2014 stood at $1.8 billion (up 20.73% YoY), and the FY2014 full-year result was $1.8 billion, up 20.73% from the prior year.
- Raw Materials was $1.8 billion for Q4 2014 at Gsk, up from $1.5 billion in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.8 billion in Q4 2014 to a low of $1.5 billion in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Asml Holding | 618.86 Bn | 602.88 Bn | 5.90 Bn |
| 2 | Hsbc Holdings | 361.40 Bn | 361.40 Bn | - |
| 3 | General Electric | 329.38 Bn | 320.03 Bn | 6.95 Bn |
| 4 | Astrazeneca | 253.73 Bn | 248.44 Bn | 12.86 Bn |
| 5 | Citigroup | 228.07 Bn | -2,074.24 Bn | 24.75 Bn |
| 6 | Bhp | 216.09 Bn | 197.55 Bn | - |
| 7 | Rio Tinto | 203.71 Bn | 199.33 Bn | - |
| 8 | Diageo | 197.36 Bn | 195.32 Bn | - |
| 9 | Unilever | 139.15 Bn | 132.12 Bn | - |
| 10 | Gsk | 101.53 Bn | 101.53 Bn | 15.97 Bn |